Drug eluting stents for everyone and everything?

Catheterization and Cardiovascular Interventions

Volumn 66, Issue 4, 2005, Pages 512-513

  Laham, Roger J ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORONARY ARTERY DISEASE; DRUG ELUTING STENT; NOTE; PERCUTANEOUS CORONARY INTERVENTION; RESTENOSIS; REVASCULARIZATION; RISK BENEFIT ANALYSIS; SAPHENOUS VEIN GRAFT;

BLOOD VESSEL PROSTHESIS IMPLANTATION; COATED MATERIALS, BIOCOMPATIBLE; CORONARY RESTENOSIS; HUMANS; METALS; PROSTHESIS DESIGN; STENTS; TREATMENT OUTCOME;

EID: 28844491281     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.20545     Document Type: Note

References (17)

1. Baim DS, Wahr D, George B, Leon MB, Greenberg J, Cutlip DE, Kaya U, Popma JJ, Ho KK, Kuntz RE. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002;105:1285-1290.
2. Laham RJ, Ho KK, Baim DS, Kuntz RE, Cohen DJ, Carrozza JP, Jr. Multivessel Palmaz-Schatz stenting: early results and one-year outcome. J Am Coll Cardiol 1997;30:180-185.
3. Pasquetto G, Reimers B, Favero L, Sacca S, Cernetti C, Napodano M, Piccolo P, Pascotto P. Distal filter protection during percutaneous coronary intervention in native coronary arteries and saphenous vein grafts in patients with acute coronary syndromes. Ital Heart J 2003;4:614-619.
4. Peykar S, Angiolillo DJ, Bass TA, Costa MA. Saphenous vein graft disease. Minerva Cardioangiol 2004;52:379-390.
5. Cohen DJ, Murphy SA, Baim DS, Lavelle TA, Berezin RH, Cutlip DE, Ho KK, Kuntz RE. Cost-effectiveness of distal embolic protection for patients undergoing percutaneous intervention of saphenous vein bypass grafts: results from the SAFER trial. J Am Coll Cardiol 2004;44:1801-1808.
6. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent study group. N Engl J Med 1994;331:489-495.
7. Savage MP, Fischman DL, Rake R, Leon MB, Schatz RA, Penn I, Nobuyoshi M, Moses J, Hirshfeld J, Heuser R, et al. Efficacy of coronary stenting versus balloon angioplasty in small coronary arteries. Stent Restenosis Study (STRESS) Investigators. J Am Coll Cardiol 1998;31:307-311.
8. Bhargava B, Kornowski R, Mehran R, Kent KM, Hong MK, Lansky AJ, Waksman R, Pichard AD, Satler LF, Leon MB. Procedural results and intermediate clinical outcomes after multiple saphenous vein graft stenting. J Am Coll Cardiol 2000;35:389-397.
9. Graberg L, Hong MK, Mehran R, Mintz GS, Kornowski R, Lansky AJ, Kent KM, Pichard AD, Satler LF, Dangas G, et al. In-hospital and long-term results of stent deployment compared with balloon angioplasty for treatment of narrowing at the saphenous vein graft distal anastomosis site. Am J Cardiol 1999;84:1381-1384.
10. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
11. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, Kozuma K, Van Langenhove G, Sousa AG, Falotico R, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001;104:2007-2011.
12. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004;109:1942-1947.
13. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A, Degertekin M, Tanabe K, Daemen J, Liu TK, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004;109:190-195.
14. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130.
15. Zahn R, Hamm CW, Zeymer U, Schneider S, Nienaber CA, Richardt G, Keim M, Levenson B, Bonzel T, Tebbe U, et al. "Real life" use of sirolimus-eluting coronary stents in Germany. Results from the prospective multi-centre German Cypher Registry. Z Kardiol 2004;93:287-294.
16. Vermeersch P, Van Langenhove G, Verheye S, Convens C, Stockman D, Van den Branden F, Van Den Heuvel P, Middelheim A. First randomized trial comparing sirolimus-eluting versus bare metal stents in severely diseased saphenous vein graft treatment: six-month clinical and angiographic outcome. J Am Coll Cardiol 2005;45:84A.
17. Hoye A, Lemos PA, Arampatzis CA, Saia F, Tanabe K, Degertekin M, Hofma S, McFadden E, Sianos G, Smits PC, et al. Effectiveness of the sirolimus-eluting stent in the treatment of saphenous vein graft disease. J Invasive Cardiol 2004;16:230-233.